REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

I-Mab Inc. (China)

Main Activities: Pharmaceutical Preparation Manufacturing | General Merchandise Stores
Full name: I-Mab Inc. Profile Updated: March 15, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English & Chinese Download a sample report

I-Mab HK is a biotech company with a global reach. The company focuses on developing and potentially commercializing immunotherapies for the treatment of cancer, as well as innovative treatments for people with serious blood disorders and cancers. Listed on NASDAQ under the symbol IMAB.

Headquarters
Suite 802, West Tower, Omnivision, 88 Shangke Road, Pudong District
Shanghai; Shanghai; Postal Code: 201210

Contact Details: Purchase the I-Mab Inc. report to view the information.

Website: http://www.i-mabbiopharma.com

Basic Information
Total Employees:
Purchase the I-Mab Inc. report to view the information.
Outstanding Shares:
Purchase the I-Mab Inc. report to view the information.
Financial Auditors:
Purchase the I-Mab Inc. report to view the information.
Incorporation Date:
2016
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
President
Purchase this report to view the information.
President
Purchase this report to view the information.
Chief Executive Officer
Purchase this report to view the information.
Chief Financial Officer
Ownership Details
Purchase this report to view the information.
15.3%
Purchase this report to view the information.
15.3%
Purchase this report to view the information.
8.6%
Purchase this report to view the information.
6.3%
Purchase this report to view the information.
6%
Subsidiaries
Chengdu Tasgen Bio-Tech Co., Ltd.
I-Mab Bio-Tech (Tianjin) Co., Ltd.
I-Mab Biopharma (Shanghai) Co., Ltd.
Company Performance
Financial values in the chart are available after I-Mab Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CNY. Absolute financial data is included in the purchased report.
Net sales revenue
-62.1%▼
Total operating revenue
69.06%▲
Operating profit (EBIT)
23.76%▲
Net Profit (Loss) for the Period
26.18%▲
Total assets
-29.65%▼
Total equity
-39.08%▼
Operating Profit Margin (ROS)
-2054.58%▼
Net Profit Margin
-1913.1%▼
Return on Equity (ROE)
-5.51%▼
Quick Ratio
-2.68%▼
Cash Ratio
-2.73%▼

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo